drugset / Trial / NCT05214495

Omega-3 Hydrogel and Prevention of Oral Mucositis

NCT05214495

Phase 2/3 Completed 36 enrolled Basma Morsy
RandomizedParallel-groupOpen-labelPrevention

Summary

Oral mucositis (OM) is recognized as one of the most frequent debilitating sequela encountered by head and neck cancer (HNC) patients treated by radiotherapy. The objective of the study is to assess primarily the effect of topical oral Omega-3 hydrogel in prevention of radiation-induced oral mucositis and secondarily, to test the effect of topical oral Omega-3 hydrogel on oral microbiome.

Timeline

Start
2022-02-09
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Omega-3 fatty acids Unknown Topical

Indications